Nembutal® CII Sodium Solution
(pentobarbital sodium injection, USP)

• Nembutal is a member of the barbiturate class of medications.
• Nembutal is a sterile solution for intravenous or intramuscular injection in 20 mL and 50 mL multiple-dose vials.

__________________________________________________________________________________

Indication
NEMBUTAL® (pentobarbital sodium injection, USP) is indicated for use as a sedative, a hypnotic for short-term treatment of insomnia, preanaesthetic and as an anticonvulsant in the emergency control of certain acute convulsive episodes, such as those associated with status epilepticus, cholera, eclampsia, meningitis, tetanus and toxic reactions to strychinne or local anesthetics.

Important Safety Information
NEMBUTAL is contraindicated in patients with a known hypersensitivity to any barbiturate, manifest or latent porphyria. Barbiturates including NEMBUTAL may be habit forming. Abrupt discontinuation may result in withdrawal symptoms, including delirium, convulsions and possibly death. Too rapid of an intravenous administration may cause respiratory depression, apnea, laryngospasm, or vasodilation with fall in blood pressure.

Concomitant use of alcohol or other CNS depressants may produce additive CNS depressant effects. Barbiturates should be administered with caution, if at all, to patients who are mentally depressed, have suicidal tendencies, chronic or acute pain. Barbiturates can cause fetal damage and infants may have withdrawal symptoms if mothers receive barbiturates. Withdrawal symptoms occur in infants born to mothers who receive barbiturates during the last trimester of pregnancy. Prolonged treatment with barbiturates should be monitored.

The most commonly reported adverse event (>1 in 100 patients) is somnolence.

For more information, please see Full Prescribing Information.

® Trademark of Lundbeck Inc., Deerfield, IL 60015, U.S.A.